

the HCDR3 comprises SEQ ID NO: 31,
the LCDR1 comprises SEQ ID NO: 43,
the LCDR2 comprises SEQ ID NO: 44, and
the LCDR3 comprises SEQ ID NO: 45.

In another aspect of the present disclosure, there is provided a nucleic acid comprising a sequence encoding SEQ ID NO: 35, 52, 39, or 46.

In a further aspect of the present disclosure, there is provided a vector comprising the nucleic acid disclosed herein.

In another aspect of the present disclosure, there is provided a composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.

In another aspect of the present disclosure, there is provided a cell comprising the vector disclosed herein.

In a further aspect of the present disclosure, there is provided a cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.

In a further aspect of the present disclosure, there is provided a process of producing an antibody comprising culturing the cell disclosed herein under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.

In another aspect of the present disclosure, there is provided an antibody produced by the process disclosed herein.

In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising the antibody disclosed herein, and a pharmaceutically acceptable excipient, diluent or carrier.

In another aspect of the present disclosure, there is provided an antibody disclosed herein for use in therapy.

In a further aspect of the present disclosure, there is provided an antibody disclosed herein, or the pharmaceutical composition disclosed herein, for use in the treatment of a B cell associated disorder, wherein the B cell associated disorder is an autoimmune disease.

In another aspect of the present disclosure, there is provided use of the antibody disclosed herein, in the manufacture of a medicament for the treatment of a B cell associated disorder, wherein the B cell associated disorder is an autoimmune disease.

CLAIMS:

1. An antibody that binds human CD19, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein
 - the HCDR1 comprises SEQ ID NO: 29,
 - the HCDR2 comprises SEQ ID NO: 30,
 - the HCDR3 comprises SEQ ID NO: 31,
 - the LCDR1 comprises SEQ ID NO: 32,
 - the LCDR2 comprises SEQ ID NO: 33, and
 - the LCDR3 comprises SEQ ID NO: 34.
2. The antibody of claim 1, wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 41.
3. The antibody of claim 1 or 2, wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO: 35 and a light chain (LC) comprising SEQ ID NO: 39.
4. The antibody of claim 1 or 2, wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 39.
5. An antibody that binds human CD19, wherein the antibody comprises a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein
 - the HCDR1 comprises SEQ ID NO: 29,
 - the HCDR2 comprises SEQ ID NO: 30,
 - the HCDR3 comprises SEQ ID NO: 31,
 - the LCDR1 comprises SEQ ID NO: 43,
 - the LCDR2 comprises SEQ ID NO: 44, and

the LCDR3 comprises SEQ ID NO: 45.

6. The antibody of claim 5, wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 48.
7. The antibody of claim 5 or 6, wherein the antibody comprises a HC comprising SEQ ID NO: 35 and a LC comprising SEQ ID NO: 46.
8. The antibody of claim 5 or 6, wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 46.
9. The antibody of any one of claims 1-8, wherein the antibody is a non-depleting antibody.
10. A nucleic acid comprising a sequence encoding SEQ ID NO: 35, 52, 39, or 46.
11. A vector comprising the nucleic acid of claim 10.
12. The vector of claim 11, wherein the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second nucleic acid sequence encoding SEQ ID NO: 39 or 46.
13. A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.
14. A cell comprising the vector of claim 12.
15. A cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.

16. The cell of claim 14 or 15, wherein the cell is a mammalian cell.
17. A process of producing an antibody comprising culturing the cell of any one of claims 14-16 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
18. An antibody produced by the process of claim 17.
19. A pharmaceutical composition comprising the antibody of any one of claims 1-9 or 18, and a pharmaceutically acceptable excipient, diluent or carrier.
20. The antibody of any one of claims 1-9 or 18 for use in therapy.
21. The antibody of any one of claims 1-9 or 18, or the pharmaceutical composition of claim 19, for use in the treatment of a B cell associated disorder, wherein the B cell associated disorder is an autoimmune disease.
22. The antibody or pharmaceutical composition for use of claim 21, wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, neuromyelitis optica, ANCA vasculitis, or myasthenia gravis.
23. Use of the antibody of any one of claims 1-9 or 18, in the manufacture of a medicament for the treatment of a B cell associated disorder, wherein the B cell associated disorder is an autoimmune disease.
24. The use of claim 23, wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, neuromyelitis optica, ANCA vasculitis, or myasthenia gravis.